GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
CytoMed Therapeutics Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026
$0.85−0.03 (-3.17%)
Close on Oct 19, 2026
Margins
Share of revenue, fiscal years 2019 to 2025
Net margin
-1227.1%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +366.7% | – | – | – |
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -51.3% | |
| Return on assets | – | – | -44.1% | |
| Current ratio | – | – | 5.17 | |
| Debt to equity | – | – | 0.06 | |
| Capex to revenue | – | – | 196.6% | |
| Diluted shares | – | 6M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
CytoMed Therapeutics generated 13.05M SGD from operations and spent 3.15M SGD on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
13.05M SGD
Used
3.15M SGD
Capital expenditure3.15M SGD100%Dividends0 SGD0%Share buybacks0 SGD0%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-1227.1%
×Asset turnover0.04×
×Equity multiplier1.16×
=Return on equity, FY2025-51.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -1227.1% | 0.04× | 1.16× | -51.3% |
| FY2024 | -3621.1% | 0.01× | 1.11× | -24.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-3.98M SGD
- Cash generatingOperating cash flow above zero-3.70M SGD
- Return on assets improvedROA up on the prior year-20.3% → -39.5%
- Earnings backed by cashOperating cash flow above net income-3.70M SGD vs -3.98M SGD
- Less leverageLong-term debt to assets fell3.9% → 4.6%
- Better liquidityCurrent ratio rose9.89 → 5.17
- No dilutionShare count did not rise12M → 12M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.01 → 0.03